Overview

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and tolerability of treatment with CTP-499 in non-dialysis patients associated with moderate chronic kidney disease.
Phase:
Phase 1
Details
Lead Sponsor:
Concert Pharmaceuticals